The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Estimated life years saved with trastuzumab in first-line HER2+ metastatic breast cancer from 1999 to 2013.
Mark Danese
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Deepa Lalla
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Melissa Brammer
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Eduardo Santos
Employment or Leadership Position - Genentech
Abraham Lee
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Anthony Masaquel
Employment or Leadership Position - Genentech
Stock Ownership - Genentech/Roche